# ViiV Healthcare clinical trials: 267 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 267 trials with ViiV Healthcare as lead sponsor, 15 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by ViiV Healthcare: 267 rows for $13.35, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/viiv-healthcare

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 267
- Recruiting or not yet: 15
- Read on: November 19, 2026

## Trials

The 25 newest of 267, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07939594 | An Evaluation of the Potential for VH4011499 Drug-drug-interactions | ViiV Healthcare | Phase 1 | Not yet recruiting | HIV Infections | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939594) |
| November 13, 2026 | NCT07934719 | Mass Balance and Absolute Bioavailability of \[14C\]-VH4011499 | ViiV Healthcare | Phase 1 | Not yet recruiting | HIV Infections | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934719) |
| September 16, 2026 | NCT07822477 | A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIV | ViiV Healthcare | Phase 1 | Not yet recruiting | HIV Infections | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822477) |
| September 14, 2026 | NCT07818915 | A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult Participants | ViiV Healthcare | Phase 1 | Recruiting | HIV Infections | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818915) |
| September 11, 2026 | NCT07816250 | A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY) | ViiV Healthcare | Phase 2 | Not yet recruiting | HIV Infections | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816250) |
| June 16, 2026 | NCT07650916 | A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With... | ViiV Healthcare | Phase 3 | Recruiting | HIV | 564 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07650916) |
| June 9, 2026 | NCT07636928 | Mass Balance and Absolute Oral Bioavailability of \[14C\]VH4524184 | ViiV Healthcare | Phase 1 | Recruiting | HIV Infections | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636928) |
| April 13, 2026 | NCT07525544 | A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants | ViiV Healthcare | Phase 1 | Recruiting | HIV Infections | 214 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07525544) |
| February 6, 2026 | NCT07393659 | A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for... | ViiV Healthcare | Phase 3 | Recruiting | HIV Infections | 197 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07393659) |
| December 10, 2025 | NCT07275606 | A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1 | ViiV Healthcare | Phase 1/2 | Recruiting | HIV Infections | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07275606) |
| October 2, 2025 | NCT07202546 | A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) | ViiV Healthcare | Phase 2 | Recruiting | HIV Infections | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07202546) |
| July 15, 2025 | NCT07066722 | A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults | ViiV Healthcare | Phase 1 | Completed | HIV Infections | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07066722) |
| July 8, 2025 | NCT07053384 | A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in... | ViiV Healthcare | Phase 1 | Active not recruiting | HIV Infections | 107 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07053384) |
| May 14, 2025 | NCT06970223 | A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to... | ViiV Healthcare | Phase 1 | Active not recruiting | HIV Infections | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06970223) |
| January 22, 2025 | NCT06786520 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From... | ViiV Healthcare | Phase 1 | Active not recruiting | HIV Infections | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06786520) |
| December 19, 2024 | NCT06741397 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered... | ViiV Healthcare | Phase 2 | Active not recruiting | HIV Infections | 229 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06741397) |
| December 9, 2024 | NCT06724640 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV | ViiV Healthcare | Phase 1 | Recruiting | HIV Infections | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06724640) |
| November 19, 2024 | NCT06694805 | A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With... | ViiV Healthcare | Phase 3 | Active not recruiting | HIV Infections | 326 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06694805) |
| October 22, 2024 | NCT06652958 | A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV | ViiV Healthcare | Phase 1 | Terminated | HIV Infections | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06652958) |
| August 1, 2024 | NCT06533280 | VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect... | ViiV Healthcare | Phase 1 | Withdrawn | HIV Infections | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06533280) |
| April 16, 2024 | NCT06368986 | A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants | ViiV Healthcare | Phase 1 | Completed | HIV Infections | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06368986) |
| March 15, 2024 | NCT06310616 | A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female... | ViiV Healthcare | Phase 1 | Completed | HIV Infections | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06310616) |
| March 15, 2024 | NCT06310551 | First Time in Human Study of Long Acting VH4524184 Formulations | ViiV Healthcare | Phase 1 | Recruiting | HIV Infections | 348 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06310551) |
| January 19, 2024 | NCT06214052 | VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1 | ViiV Healthcare | Phase 2 | Completed | HIV Infections | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06214052) |
| December 13, 2023 | NCT06168318 | A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral... | ViiV Healthcare | Phase 1 | Completed | HIV Infections | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06168318) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 129 |
| Phase 1/2 | 2 |
| Phase 2 | 38 |
| Phase 2/3 | 3 |
| Phase 3 | 51 |
| Phase 4 | 16 |
| Not applicable | 6 |
| Observational | 22 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 209 |
| Terminated | 19 |
| Active not recruiting | 12 |
| Recruiting | 11 |
| Withdrawn | 5 |
| Not yet recruiting | 4 |
| No longer available | 3 |
| Unknown | 2 |
| Available | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| HIV Infections | 156 |
| Acquired Immunodeficiency Syndrome | 152 |
| Infections | 123 |
| Hepatitis | 4 |
| Tuberculosis | 2 |
| Hepatitis B, Chronic | 2 |
| Sexually Transmitted Diseases | 2 |
| Renal Insufficiency | 2 |
| Cardiovascular Diseases | 1 |
| Virus Diseases | 1 |
| Seizures | 1 |
| Fractures, Bone | 1 |
| Injection Site Reaction | 1 |
| Hepatitis B | 1 |
| Hepatitis C, Chronic | 1 |
| Coinfection | 1 |
| Immunologic Deficiency Syndromes | 1 |
| Retroviridae Infections | 1 |
| HIV-Associated Lipodystrophy Syndrome | 1 |
| Liver Diseases | 1 |
| Hepatitis, Chronic | 1 |
| Hypersensitivity | 1 |
| Arthralgia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pediatric clinics in the United States](https://specstream.ai/data/businesses/pediatric-clinics/united-states)
- [Elevator companies in the United States](https://specstream.ai/data/businesses/elevator-companies/united-states)
- [Walk-in clinics in the United States](https://specstream.ai/data/businesses/walk-in-clinics/united-states)
- [Medical billing companies in the United States](https://specstream.ai/data/businesses/medical-billing-companies/united-states)
- [Commercial refrigeration companies in the United States](https://specstream.ai/data/businesses/commercial-refrigeration-companies/united-states)
- [Stock brokers in the United States](https://specstream.ai/data/businesses/stock-brokers/united-states)
